Although the dust may have settled from a Canadian lawsuit Eli Lilly lost over patents for two of its drugs, Zyprexa and Strattera, questions remain over the manner in which the Indianapolis-based company fought in court.

The FDA approved Neos’ Cotempla XR-ODT, the first methylphenidate extended-release orally disintegrating tablet for treating ADHD in patients 6 to 17 years old.

Alcobra Ltd. said it would abandon evaluating its only experimental drug to treat attention deficit hyperactivity disorder (ADHD) after a failed late-stage study.

Giving stimulants to kids with attention deficit hyperactivity disorder (ADHD) may not help them complete homework or get better grades, a small study suggests.

Strong demand for Shire’s top-selling Vyvanse drug helped to lift the company’s first-quarter earnings by better-than-expected 12 percent.

Neos Therapeutics Inc’s drug to treat a common type of childhood behavioral disorder was approved by the U.S. Food and Drug Administration, making it the first of its kind to win U.S. approval. The drug, Adzenys XR-ODT, is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six and older. The […]

Researchers voiced concern on Wednesday about poor quality studies on the popular ADHD treatment Ritalin, saying evidence of some benefits, but also of sleep problems and appetite loss, suggests the drug should be prescribed with caution. Ritalin is sold by Swiss pharmaceutical firm Novartis NOVN.VX, known generically as methylphenidate and also sold under the brand […]

Children with ADHD (attention deficit hyperactivity disorder) show signs of improvement after playing a videogame for 30 minutes a day rather than taking a pill, the U.S. company developing the treatment said on Wednesday. Diagnoses for ADHD have risen in recent decades, and some 9.5 percent of children aged 3-17 in the United States had […]

Dallas/Fort Worth, Texas-based Neos Therapeutics announced yesterday that the U.S. Food and Drug Administration (FDA) had found deficiencies in its New Drug Application (NDA) for Cotempla XR-ODT to treat attention deficit hyperactivity disorder (ADHD). As a result, they would not be discussing labeling and postmarketing requirements until further review.   Neos focuses on developing and […]

Very premature babies are known to have an increased risk for attention-deficit hyperactivity disorder (ADHD), and a new study suggests this may be true also for babies born only slightly early. “There has been quite a lot of research on very preterm birth and the increased risk for ADHD but less evidence when it comes […]